Evan Seffar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Evan Seffar has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Charles-Frédéric Mantion
Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, Besançon, France
26 shared publications - Francine Garnache-Ottou
Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, Besançon, France
26 shared publications - Mathieu Gonçalves-Venturelli
Lymphobank SAS, Besancon, France
26 shared publications - Maxime Fredon
Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, Besançon, France
26 shared publications - Olivier Adotévi
Université Marie et Louis Pasteur, EFS, INSERM, UMR RIGHT, Besançon 25000, France; Department of Medical Oncology, University Hospital of Besançon, Besançon 25000, France
26 shared publications - Yann Godet
Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, Besançon, France
26 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S2: Characterization of CD123 CAR-T.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S2: Characterization of CD123 CAR-T.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S1: Design of five CD123 CAR-T constructs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S1: Design of five CD123 CAR-T constructs.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S4 Effect of CD123 CAR-T on humanized mouse model, NSG-SGM3.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S4 Effect of CD123 CAR-T on humanized mouse model, NSG-SGM3.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S3: Effect of CD123 CAR-T on human Hematopoietic stem cell.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S3: Effect of CD123 CAR-T on human Hematopoietic stem cell.
- Open Access
- 4 May 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (5) , e014346
Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma
Background: The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib delays disease progression in dedifferentiated liposarcoma (DDLPS) by inducing tumor cell quiescence or senescence, though most tumors ultimately progress. Preclinical data suggest CDK4/6 inhibition enhances intratumoral inflammation and may synergize with immune checkpoint inhibitors. Methods: This non-randomized, open-label, phase 2 study was conducted at Memorial Sloan Kettering Cancer Center. Patients with metastatic or unresectable DDLPS, or those expected to benefit from systemic therapy prior to surgery, were eligible. Patients received palbociclib (125 mg orally, days 1–21 of a 28-day cycle) plus retifanlimab (500 mg intravenous flat dose every 4 weeks). The primary endpoint was to assess the best objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Results: 30 patients were treated and evaluable. Median age was 61 years (range 36–81), 67% were male, and 63% were treatment-naive. The median follow-up was 14.8 months. ORR was 20% (95% CI 8% to 39%) and the clinical benefit rate was 53% (95% CI 34% to 72%). Median progression-free survival and overall survival were 4.8 (95% CI 1.71 to 15.7) and 27 months (95% CI 21.7 to not reached (NR)), respectively. Median duration of response was 18.4 months (95% CI 9.4 months to NR). Grade ≥3 treatment-related adverse events occurred in 61% of patients, including one Grade 4 neutropenia. There were no Grade 5 events. Retifanlimab and palbociclib were discontinued due to toxicity in 23% and 17% of patients, respectively. Tumor sequencing identified JUN amplification in 6 of 14 patients with progressive disease versus 2 patients with stable disease or partial response. Patients with progressive disease had a higher median copy number alteration burden compared with those with stable disease or partial response. Conclusions: Palbociclib plus retifanlimab demonstrated deep and durable responses in a subset of patients with advanced DDLPS, with an ORR exceeding that historically observed with either agent alone. Adverse events were generally manageable. Copy number alteration burden and JUN amplification merit further evaluation as potential biomarkers of resistance. Trial registration number: https://clinicaltrials.gov/study/NCT04438824 .
- 4 May 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (5) , e014346
Open AccessPhase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma
Background: The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib delays disease progression in dedifferentiated liposarcoma (DDLPS) by inducing tumor cell quiescence or senescence, though most tumors ultimately progress. Preclinical data suggest CDK4/6 inhibition enhances intratumoral inflammation and may synergize with immune checkpoint inhibitors. Methods: This non-randomized, open-label, phase 2 study was conducted at Memorial Sloan Kettering Cancer Center. Patients with metastatic or unresectable DDLPS, or those expected to benefit from systemic therapy prior to surgery, were eligible. Patients received palbociclib (125 mg orally, days 1–21 of a 28-day cycle) plus retifanlimab (500 mg intravenous flat dose every 4 weeks). The primary endpoint was to assess the best objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Results: 30 patients were treated and evaluable. Median age was 61 years (range 36–81), 67% were male, and 63% were treatment-naive. The median follow-up was 14.8 months. ORR was 20% (95% CI 8% to 39%) and the clinical benefit rate was 53% (95% CI 34% to 72%). Median progression-free survival and overall survival were 4.8 (95% CI 1.71 to 15.7) and 27 months (95% CI 21.7 to not reached (NR)), respectively. Median duration of response was 18.4 months (95% CI 9.4 months to NR). Grade ≥3 treatment-related adverse events occurred in 61% of patients, including one Grade 4 neutropenia. There were no Grade 5 events. Retifanlimab and palbociclib were discontinued due to toxicity in 23% and 17% of patients, respectively. Tumor sequencing identified JUN amplification in 6 of 14 patients with progressive disease versus 2 patients with stable disease or partial response. Patients with progressive disease had a higher median copy number alteration burden compared with those with stable disease or partial response. Conclusions: Palbociclib plus retifanlimab demonstrated deep and durable responses in a subset of patients with advanced DDLPS, with an ORR exceeding that historically observed with either agent alone. Adverse events were generally manageable. Copy number alteration burden and JUN amplification merit further evaluation as potential biomarkers of resistance. Trial registration number: https://clinicaltrials.gov/study/NCT04438824 .
- Open Access
- 27 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
Supplementary Table S5. Transcriptome-wide differential gene expression between cluster 8 of P12 vs. all other P12 clusters.
- 27 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
Supplementary Table S5. Transcriptome-wide differential gene expression between cluster 8 of P12 vs. all other P12 clusters.
- Open Access
- 27 February 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
Clinical trial design and efficacy. A, Study schema depicting treatment and biopsy collection time points. B, Flow diagram of treatment and follow-up for patients in the safety lead-in and trial expansion cohorts. C, Waterfall plot showing best percent tumor volume change from baseline per RECIST 1.1. One patient who was not evaluable for response by RECIST 1.1 is excluded. irAE(+), solid circles indicate irAEs; SC+, single-cell data from tumor biopsies, in which filling of the left and right halves indicates analyzability at the pre- and post-retifanlimab time points, respectively. D, Spider plot showing percent change in sum of target lesion diameters over time in patients who were evaluable for response by RECIST v1.1. E, Swimmer plot showing patient PFS. Dashed line indicates median PFS. NE, not evaluable; OR, overall response.
- 27 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
Clinical trial design and efficacy. A, Study schema depicting treatment and biopsy collection time points. B, Flow diagram of treatment and follow-up for patients in the safety lead-in and trial expansion cohorts. C, Waterfall plot showing best percent tumor volume change from baseline per RECIST 1.1. One patient who was not evaluable for response by RECIST 1.1 is excluded. irAE(+), solid circles indicate irAEs; SC+, single-cell data from tumor biopsies, in which filling of the left and right halves indicates analyzability at the pre- and post-retifanlimab time points, respectively. D, Spider plot showing percent change in sum of target lesion diameters over time in patients who were evaluable for response by RECIST v1.1. E, Swimmer plot showing patient PFS. Dashed line indicates median PFS. NE, not evaluable; OR, overall response.
- Open Access
- 27 February 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
Changes in proportions of T-cell populations with anti–PD-1 via high-parameter flow cytometry. A, Change in abundance of T-cell subtypes with initiation of retifanlimab in patients with paired biopsies and detectable tumor-infiltrating T cells. B, Boxplot depicting percent change post- vs. pre-retifanlimab in the abundance of 63 T cell types. Filled boxes with bold labels and asterisks indicate T cell subsets with significant changes (P < 0.05; FDR < 0.05). C and D, Percent change in four key subsets of (C) CD4+ and (D) CD8+ T cells. OR, overall response.
- 27 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
Changes in proportions of T-cell populations with anti–PD-1 via high-parameter flow cytometry. A, Change in abundance of T-cell subtypes with initiation of retifanlimab in patients with paired biopsies and detectable tumor-infiltrating T cells. B, Boxplot depicting percent change post- vs. pre-retifanlimab in the abundance of 63 T cell types. Filled boxes with bold labels and asterisks indicate T cell subsets with significant changes (P < 0.05; FDR < 0.05). C and D, Percent change in four key subsets of (C) CD4+ and (D) CD8+ T cells. OR, overall response.
- Open Access
- 27 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
Supplementary Figure S1. Survival. A) Kaplan-Meier curve for progression-free survival. B) Kaplan-Meier curve for overall survival.
- 27 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
Supplementary Figure S1. Survival. A) Kaplan-Meier curve for progression-free survival. B) Kaplan-Meier curve for overall survival.
- Open Access
- 27 February 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
Table 1 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
- 27 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
Table 1 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma